Apixaban shows more efficacy and safety than rivaroxaban in patients with atrial fibrillation and valvular heart disease

Among patients diagnosed with atrial fibrillation (AF) and valvular heart disease (VHD), those treated with apixaban have achieved a lower rate of ischemic stroke or systemic embolism and a lower rate of intracranial or gastrointestinal bleeding than those treated with rivaroxaban. Researchers from a large retrospective study reported these findings on Oct 18, 2022 in the Annals of Internal Medicine. […]